LiDCO Group plc : Result of AGM
06/13/2012| 09:24am US/Eastern
Recommend:
("LiDCO" or the "Company")
Result of AGM
LiDCO Group Plc (AIM:LID), the UK-based hemodynamic
monitoring company, announces that all resolutions proposed
at the Company's Annual General Meeting held today at
11am at the offices of Abchurch Communications, 125 Old Broad
Street, London EC2N 1AR, were duly passed.
- Ends -
For further information, please contact:
|
LiDCO Group Plc
|
|
|
Terry O'Brien (CEO)
|
Tel: +44 (0)20 7749 1500
|
|
Paul Clifford (Finance Director)
|
|
|
John Rowland (Company Secretary)
|
|
|
FinnCap
|
|
|
Geoff Nash / Henrik Persson
Stephen Norcross (broking)
|
Tel: +44 (0)20 7600 1658
|
Media enquiries:
|
Abchurch
|
|
|
Sarah Hollins / Adam Michael / Joanne Shears /
Jamie Hooper
|
Tel: +44 (0) 20 7398 7719
|
|
Jamie.hooper@abchurch-group.com
|
|
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic
monitoring equipment and disposables to hospitals. These
products are used primarily for the management of adult
hospital patients requiring critical care or at major
cardiovascular risk. LiDCO's computer-based technology
can significantly reduce the complications (particularly
infections) and costs associated with major surgery. The
technology was invented in the Department of Applied
Physiology based at St Thomas' Hospital, London. LiDCO is
based in the UK and its shares are traded on AIM. For more
information please see www.lidco.com.
The Company's sales office is in Cambridge, its
manufacturing facility / general administration base is in
Hoxton, London, and its current products are:
* LiDCOplus is a computer-based platform monitor used
in the Intensive Care Unit for real-time continuous display
of hemodynamic parameters including cardiac output, oxygen
delivery and fluid-volume responsiveness (PPV% and
SVV%)
* LiDCOrapid: our new cardiac output monitor designed
specifically for use in the Operating Theatre for fluid and
drug management. The monitor enables acute-care physicians to
get accurate and immediate feedback on the patient's
fluid and hemodynamic status - a key measure of overall
well-being both during and after surgery. These benefits
are:
|
·
|
Early and rapid warning of change
|
|
·
|
Clear indication of therapeutic route: fluid or
drug
|
|
·
|
Quantification of hemodynamic response,
particularly stroke volume
|
|
·
|
Permits more effective delivery of fluids - the
right amount at the right time
|
|
·
|
Advanced hemodynamic care has been shown to
contribute to:
- Reduced morbidity and complications, length of
stay & overall cost of care
|
* LiDCO single-patient-use disposables used in
conjunction with the LiDCOplus and LiDCOrapid.
* LiDCOview:an easy-to-use graphical display of
historical LiDCOplus and LiDCOrapid hemodynamic data.
* LiDCO's Distribution Network:
The Company sells via its own direct sales force to
hospitals in the UK, and in export markets predominantly
through a worldwide network of speciality critical care and
anesthesia distributors.
This information is provided by RNS
The company news service from the London Stock
Exchange
END
distributed by
|
|
Recommend :
